History of prevention of relapse -- How to measure relapse in animals -- How to measure relapse in humans -- Disulfiram (Antabuse®): the first medication to stop drinking -- Naltrexone: preclinical data -- Naltrexone: clinical data -- Acamprosate: preclinical data -- Acamprosate: clinical data -- Serotonergic compounds: preclinical data -- Serotonergic compounds: clinical data -- Opioidergic compounds: preclinical data -- Second generation opioidergic compounds: clinical data -- Dopaminergic compounds: preclinical data -- Dopaminergic compounds: clinical data -- Baclofen: preclinical data -- Baclofen: clinical data -- Cannabinoid receptor antagonists: a perspective -- Neuropeptide Y antagonists: a perspective -- Glutamatergic compounds: a perspective -- Future perspectives on relapse prevention
Summary
"This book gives a comprehensive overview about different neurotransmitter/peptide systems involved in craving and relapse behavior and critically describes the clinical application of new anti-craving and anti-relapse compounds. The editors compiled the most recent available preclinical and clinical data, offering a thorough picture on modern relapse prevention. Undoubtedly, this book sets out to provide an all-encompassing overview about the topic, which will be of interest to the preclinical researcher, the clinician as well as to the patient who wants to learn more."--Jacket
